Cold solutions are more viscous, which can create measurement differences compared to room-temperature draws
Clinical context separates them
Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study Roos I, Sharmin S, Horakova D, Kubala Havrdova E, Libertinova J, Vachova M, Alroughani R, Boz C, Rous Z, Buzzard K, Skibina O, Peterka M, Hradilek P, Mares M, Coles A, Brown JWL, Eichau Madueo S, Foschi M, Prevost J, Terzi M, Prat A, Girard M, Meca-Lallana JE, John N, Blanco Y, van der Walt A, Butzkueven H, Recmanova E, Laureys G, Ampapa R, Macdonell R, Pavelek Z, Khoury SJ, D'Amico E, Gerlach O, Van Pesch V, Maimone D, Romero-Ferrando B, McCombe PA, Mrabet S, Willekens B, Crdenas-Robledo S, Ramo-Tello C, Stourac P, Houskova J, Shaygannejad V, Hodgkinson S, Cartechini E, Kermode AG, Fabis-Pedrini M, Carroll WM, Slee M, Snchez-Menoyo JL, Al-Asmi A, Mathey G, Giannesini C, Michel L, Ciron J, De Sze J, Ruet A, Kwiatkowski A, Zephir H, Papeix C, Lebrun-Frenay C, Moreau T, Berger E, Clavelou P, Pelletier J, Casez O, Bourre B, Wahab A, Magy L, Camdessanch JP, Doghri I, Tchikviladze M, Sellebjerg F, Romme Christensen J, Jensen HB, Illes Z, Bramow S, Rasmussen PV, Stilund ML, Schfer J, Kant M, Weglewski A, Vukusic S, Magyari M, Laplaud DA, Kalincik T
Studies in animal colitis models show that BPC-157 may protect the lining of the stomach and intestines and reduce inflammatory damage, supporting mucosal healing in conditions resembling colitis and gastritis
DISCLAIMER: This product has not been evaluated by the FDA and is solely for research only
